Implementing the Kidney Health Initiative Surrogate Efficacy Endpoint in Patients With IgA Nephropathy (the PROTECT Trial)

類似資料

• Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy
  著者:: Thompson, Aliza, 等
  出版事項: (2019)
• Why Target the Gut to Treat IgA Nephropathy?
  著者:: Barratt, Jonathan, 等
  出版事項: (2020)
• Aberrant Glycosylation of the IgA1 molecule in IgA Nephropathy
  著者:: Novak, Jan, 等
  出版事項: (2018)
• Biomarkers to Predict Progression in IgA Nephropathy
  著者:: Cheung, Chee Kay, 等
  出版事項: (2019)
• Characterization of IgA Deposition in the Kidney of Patients with IgA Nephropathy and Minimal Change
  著者:: Won-Hee Cho, 等
  出版事項: (2020-08-01)